TNFRSF8 and diffuse large B-cell lymphoma: CD30 is variably expressed in DLBCL and mediastinal lymphomas, and the activity and safety of BV have been documented in R/R DLBCL, both as monotherapy [162] with 44% ORR (including 17% CR) or in combination with lenalidomide, with 57% ORR and 35% CR [163].